الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 157 |  |  |
| | | from | 157 | | |
Abstract
The present work was designed to determine the effect of different doses of GnRH analogue on the sexual desire, semen parameters and ultrasonographic picture of the genital system of puberal buffalo bulls. This work was carried out on a total of nine Egyptian buffalo bulls aged 15-18 months for a period of four and half month in the farm of Faculty of Veterinary Medicine –Benha University. The experimental period was divided into three periods; before, during and after treatment by the GnRH analogue (Buserelin acetate). The period before treatment extended for six weeks as a pre-experimental period. During this period semen was collected once weekly, blood samples were collected once weekly and the bulls were examined ultrasonographically every two weeks. The period during treatment extended for six weeks as an experimental period. During this period the bulls were divided into three groups, each group contains three bulls and each received weekly a dose of GnRH analogue (Buserelin acetate, Receptal®, Intervet Intern. B.V., EU) as follow: Group I: Each bull was injected by a total dose of 8µg Buserelin acetate (2 ml Receptal) for six weeks. Group II: Each bull was injected by a total dose of 12µg Buserelin acetate (3 ml Receptal) for six weeks. Group III: Each bull was injected by a total dose of 16µg Buserelin acetate (4 ml Receptal) for six weeks. During this period Semen was collected once weekly and blood samples were collected every two weeks. The period after treatment extended for six weeks as a post-experimental period. During this period semen was collected once weekly, blood samples were collected once weekly and ultrasonographic examination was done every two weeks. By the statistical analysis of the obtained results: 1- In general, there was an improvement in the sexual behavior, semen characteristics and ultrasonographic imaging of the genital system in the period during treatment with the GnRH analogue comparing to that before and after treatment. 2- Buffalo bulls showed more sexual activity when injected by the dose of 12 µg (7.75±0.32 mints.) when compared to those injected by the 8µg (6.01±0.44 mints.) and 16µg (8.59±0.34mint.) Buserelin acetate.
3- The improvement in the reaction time is coincided with that occurred in the serum testosterone concentration which was 1.88±0.26ng/ml. with 8µg while it was 2.24±0.31 ng/ml. with 12 ug, and 1.56±0.51 ng/ml. with 16µg Buserelin acetate.
4- The ejaculate volume was 2.24±0.15 ml, 2.01±0.11 ml and 1.94±0.07 ml. for buffalo bulls injected with the 8µg, 12µg and 16µg Buserelin acetate respectively.
5- The sperm cell concentration was 899.79±33.26 x 106, 943.31±19.99 x 106 and 894.41±99.27 x 106 sperm /ml. for buffalo bulls injected by the 8µg, 12µg and 16µg Buserelin acetate respectively.
6- The sperm motility was 60.71±1.16 %, 64.22±0.67 % and 60.83±0.80 % for buffalo bulls injected by the 8µg, 12µg and 16µg Buserelin acetate respectively.
7- The sperm livability was 68.97±1.09 %, 71.65±1.23 % and 69.44±1.00 % for buffalo bulls injected by the 8µg, 12µg and 16µg Buserelin acetate respectively.
8- The total sperm abnormalities were 10.14±0.66 %, 6.16±0.55 % and 9.16±0.49 % for buffalo bulls injected by the 8µg, 12µg and 16µg Buserelin acetate respectively.
9- With the ultrasonographic examination, it was appeared that; the testicular diameter did not differed significantly before and after the different treatments. It was 5.15±0.06 cm vs 5.09±0.10 cm, 4.88±0.06 cm vs 4.86±0.08 cm and 4.80±0.18 cm vs 4.99±0.19 cm with 8 ug, 12 ug and 16 ug Buserelin acetate respectively.
10- The epididymal tail length did not differed significantly before and after treatment with the 8µg, while it differed significantly with the 12 µg and the 16 µg Buserelin acetate. It was 2.32±0.05 cm vs 2.32±0.03 cm, 2.29±0.05 cm vs 2.48±0.05cm 2.10±0.06 cm vs 2.33±0.06 cm with 8 ug, 12 ug and 16 ug Buserelin acetate respectively.
11- The epididymal tail width did not differed significantly before and after the different treatments. It was 2.17±0.05 cm vs 2.13±0.04 cm, 2.09±0.04 cm vs 2.06±0.05 cm and 1.86±0.04 cm vs 1.96±0.05 cm with 8 ug, 12 ug and 16 ug Buserelin acetate respectively.
12- The bulbo-urethral gland height did not differed significantly before and after the different treatments. It was 1.17±0.03 cm vs 1.15±0.02cm, 1.08±0.04 cm vs 1.12±0.02 cm and 1.09±0.02 cm vs 1.15±0.04 cm with 8 ug, 12 ug and 16 ug Buserelin acetate respectively.
13- The bulbo-urethral gland length differed significantly before and after treatment with the 8µg while it did not differed significantly with the 12 µg and the 16 µg Buserelin acetate. It was 2.16±0.05cm vs 2.36±0.05 cm, 2.37±0.07cm vs 2.40±0.12cm and 2.04±0.05 cm vs 1.99±0.10 cm with 8 ug, 12 ug and 16 ug Buserelin acetate respectively.
14- The Prostatic body height differed significantly before and after treatment with the 8µg and the 16 µg while it did not show any significant difference with the 12 µg Buserelin acetate. It was 1.29±0.09 cm vs 1.47±0.03cm, 1.59±0.03 cm vs 1.58±0.04cm and 1.37±0.05 cm vs 1.53±0.05cm with 8 ug, 12 ug and 16 ug Buserelin acetate respectively.
15- The disseminate prostate did not differed significantly before and after the different treatments. It was 1.26±0.06 cm vs 1.38±0.07 cm, 1.45±0.10 cm vs 1.56±0.10 cm and 1.33±0.09 cm vs 1.32±0.10 cm with 8 ug, 12 ug and 16 ug Buserelin acetate respectively.
16- The vesicular gland height differed significantly before and after the different treatments. It was 1.50±0.04cm vs 1.63±0.04 cm, 1.58±0.07 cm vs 1.81±0.05 cm and 1.39±0.06 cm vs 1.74±0.05 cm with 8 ug, 12 ug and 16 ug Buserelin acetate respectively.
17- The ampulla ductus deference height differed significantly before and after the different treatments. It was 0.49±0.01cm vs 0.62±0.01 cm, 0.60±0.02 cm vs 0.67±0.02 cm and 0.51±0.01cm vs 0.56±0.01 cm with 8 ug, 12 ug and 16 ug Buserelin acetate respectively.